정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 744 | Completed | Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts | Prophylaxis | Drug: Hydroxychloroquine | Phase 4 | Bryn Mawr Hospital, Sharpe-Strumia Research Foundation, Bryn Mawr Hospital Foundation, Cotswold Foundation | OTHER | 54 | All | 18 Years | Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States Paoli Hospital, Paoli, Pennsylvania, United States Lankenau Medical Center, Wynnewood, Pennsylvania, United States |
| 743 | Completed | RAS and Coagulopathy in COVID19 | COVID | Biological: TRV027 Other: sodium chloride 0.9% |
Early Phase 1 | Imperial College London | OTHER | 30 | All | 18 Years | Imperial College NHS Trust, London, United Kingdom |
| 742 | Recruiting | Ravulizumab and COVID-19 | Acute Kidney Injury | Drug: Ravulizumab | Phase 3 | Brigham and Women's Hospital | OTHER | 32 | All | 18 Years ~ 85 Years | Brigham and Women's Hospital, Boston, Massachusetts, United States |
| 741 | Recruiting | RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow | COVID-19 Pandemic | Drug: Dexamethasone Drug: Methylprednisolone |
Phase 4 | Cairo University | OTHER | 60 | All | 18 Years | Eman Osama, Cairo, Egypt |
| 740 | Recruiting | Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines | COVID-19 | Drug: Vaccine, COVID19 | Phase 4 | Huashan Hospital | OTHER | 400 | All | 18 Years | Huashan Hospital affiliated to Fudan University, Shanghai, Jingan, China Beijing Ditan Hospital Capital Medical University, Beijing, China |
| 739 | Active, not recruiting | Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine | Vaccine Adverse Reaction | Biological: QazCoVac-P -COVID-19 Subunit Vaccine Other: Placebo |
Phase 2 | Research Institute for Biological Safety Problems | OTHER_GOV | 244 | All | 18 Years ~ 100 Years | Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstan |
| 738 | Completed | Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine | Vaccine Adverse Reaction | Biological: QazCovid-in® - COVID-19 inactivated vaccine Other: Placebo |
Phase 2 | Research Institute for Biological Safety Problems, National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan | OTHER_GOV | 244 | All | 18 Years ~ 100 Years | Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstan |